RVL Pharmaceuticals PLC (NASDAQ:RVLP)

0.8301
BATS BZX Real-Time Price
As of 11:45am ET
 -0.0299 / -3.48%
Today’s Change
0.72
Today|||52-Week Range
2.99
-25.88%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$87.4M

Company Description

RVL Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.

Contact Information

RVL Pharmaceuticals Plc
400 Crossing Boulevard
Bridgewater New Jersey 08807
P:(908) 809-1300
Investor Relations:

Employees

Shareholders

Individual stakeholders66.61%
Other institutional22.77%
Mutual fund holders2.60%

Top Executives

Brian A. MarkisonChairman, Chief Executive & Financial Officer
James SchaubChief Operating Officer & Executive Vice President
Sergio AlegreVice President-Global Compliance
Michael J. DepetrisChief Accounting Officer
Jarret MillerExecutive Vice President-Human Resources